Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,782.81
(
2.51%
)
US TECH 100
24,186.80
(
2.73%
)
Dow Jones
47,909.92
(
2.85%
)
Brent Oil
94.84
(
-6.30%
)
Bitcoin
71,130.60
(
0.00%
)
News Focus
News Focus
Post# of 820822
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

meirluc

Send PM Follow Ignore
Followers 57
Posts 3138
Boards Moderated 0
Alias Born 02/01/2017

meirluc

Re: jondoeuk post# 442061

Monday, 02/07/2022 8:15:37 PM

Monday, February 07, 2022 8:15:37 PM

Post# of 820822
Jondoeuk, why would autologous dendritic cell vaccines prepared from recurrent GBM tumors be utilized to treat all the recurrent GBM patients in a trial (both arms), if previously, identically prepared autologous dendritic cell vaccines derived from primary GBM tumors, failed to demonstrate efficacy in the primary GBM patients?

https://clinicaltrials.gov/ct2/show/NCT04201873?term=Keytruda+and+autologous+dendritic+cell+vaccine&cond=Recurrent+Glioblastoma&draw=2&rank=1



Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News